Victor Tse1,2, Jussi Sillanpaa1, Ann Y Minn1, Ming Teng1, Fu Xiaoyang1, Amy Gillis1, Laura Millender1, William Sheridan1,2, William Wara1. 1. Department of Radiation Oncology, Kaiser Permanente Comprehensive Cancer Treatment Center, 220 Oyster Point Blvd., South San Francisco, CA 94080, USA. 2. Department of Neurosurgery, Kaiser Permanente Northern California Neuroscience Center, Tower Building 3rd Floor, 1150 Veterans Blvd., Redwood City, CA 94063, USA.
Abstract
BACKGROUND: Glomus tumors are difficult to manage surgically because they are vascular tumors that are topographically associated with important vascular and neuronal structures. Hence, there is a strong risk of incomplete resection and a high morbidity rate. In addition, they grow slowly. Recent treatments have increasingly involved a combination of surgical resection and radiosurgery. We present our experience in treating glomus tumors of the skull base with stereotactic radiosurgery as an upfront therapy. METHODS: We analyzed data from 13 consecutive patients with glomus tumors that were initially treated with stereotactic radiosurgery in our institute from February 2010 to April 2012. The tumor control rate, resolution of symptoms, and the complication rate were tabulated. RESULTS: All patients were female with a median age of 63 (mean 62.7+/-14.6 years). The median treatment dose was 25.8 Gy (27.6 Gy +/- 9.5 Gy) and the median tumor volume 10.4 mL (9.2 +/- 6.5). The median follow-up was 47.4 months (51.8+/-11.2 months, range 31-74). The tumor control rate was 92.3%; 46.7% of the patients had noticeable tumor shrinkage. This happened at a median interval of 17 months (18.7+/-6.8) after treatment. Most patients with tinnitus had resolution of their symptoms (87.5%). Four patients presented with new symptoms and four patients with worsening of pre-existing symptoms. The time course of symptomatic improvement followed that of tumor size reduction. However, there was no statistical correlation between the amount of tumor reduction and symptomatic relief. CONCLUSION: Stereotactic radiosurgery (SRS) is an effective upfront treatment option in the management of glomus tumors.
BACKGROUND: Glomus tumors are difficult to manage surgically because they are vascular tumors that are topographically associated with important vascular and neuronal structures. Hence, there is a strong risk of incomplete resection and a high morbidity rate. In addition, they grow slowly. Recent treatments have increasingly involved a combination of surgical resection and radiosurgery. We present our experience in treating glomus tumors of the skull base with stereotactic radiosurgery as an upfront therapy. METHODS: We analyzed data from 13 consecutive patients with glomus tumors that were initially treated with stereotactic radiosurgery in our institute from February 2010 to April 2012. The tumor control rate, resolution of symptoms, and the complication rate were tabulated. RESULTS: All patients were female with a median age of 63 (mean 62.7+/-14.6 years). The median treatment dose was 25.8 Gy (27.6 Gy +/- 9.5 Gy) and the median tumor volume 10.4 mL (9.2 +/- 6.5). The median follow-up was 47.4 months (51.8+/-11.2 months, range 31-74). The tumor control rate was 92.3%; 46.7% of the patients had noticeable tumor shrinkage. This happened at a median interval of 17 months (18.7+/-6.8) after treatment. Most patients with tinnitus had resolution of their symptoms (87.5%). Four patients presented with new symptoms and four patients with worsening of pre-existing symptoms. The time course of symptomatic improvement followed that of tumor size reduction. However, there was no statistical correlation between the amount of tumor reduction and symptomatic relief. CONCLUSION: Stereotactic radiosurgery (SRS) is an effective upfront treatment option in the management of glomus tumors.
Entities:
Keywords:
Stereotactic radiosurgery; case series; glomus tumors; outcome study
Authors: R Liscák; V Vladyka; B Wowra; A Kemeny; D Forster; J A Burzaco; R Martinez; S Eustacchio; G Pendl; J Regis; W Pellet Journal: Acta Neurochir (Wien) Date: 1999 Impact factor: 2.216
Authors: Jason P Sheehan; Shota Tanaka; Michael J Link; Bruce E Pollock; Douglas Kondziolka; David Mathieu; Christopher Duma; A Byron Young; Anthony M Kaufmann; Heyoung McBride; Peter A Weisskopf; Zhiyuan Xu; Hideyuki Kano; Huai-che Yang; L Dade Lunsford Journal: J Neurosurg Date: 2012-06-08 Impact factor: 5.115
Authors: Robert L Foote; Bruce E Pollock; Deborah A Gorman; Paula J Schomberg; Scott L Stafford; Michael J Link; Robert W Kline; Scott E Strome; Jan L Kasperbauer; Kerry D Olsen Journal: Head Neck Date: 2002-04 Impact factor: 3.147
Authors: Stephen G Chun; Lucien A Nedzi; Kevin S Choe; Ramzi E Abdulrahman; Susie A Chen; John S Yordy; Robert D Timmerman; Joe W Kutz; Brandon Isaacson Journal: Stereotact Funct Neurosurg Date: 2014-05-07 Impact factor: 1.875
Authors: Mohammad Maarouf; Jürgen Voges; Peter Landwehr; Rainer Bramer; Harald Treuer; Martin Kocher; Rolf-Peter Müller; Volker Sturm Journal: Cancer Date: 2003-02-15 Impact factor: 6.860